These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21642381)

  • 1. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.
    Ii M; Li H; Adachi Y; Yamamoto H; Ohashi H; Taniguchi H; Arimura Y; Carbone DP; Imai K; Shinomura Y
    Clin Cancer Res; 2011 Aug; 17(15):5048-59. PubMed ID: 21642381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
    Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
    Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
    Adachi Y; Li R; Yamamoto H; Min Y; Piao W; Wang Y; Imsumran A; Li H; Arimura Y; Lee CT; Imai K; Carbone DP; Shinomura Y
    Carcinogenesis; 2009 Aug; 30(8):1305-13. PubMed ID: 19493905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
    Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
    Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
    Min Y; Adachi Y; Yamamoto H; Ito H; Itoh F; Lee CT; Nadaf S; Carbone DP; Imai K
    Cancer Res; 2003 Oct; 63(19):6432-41. PubMed ID: 14559833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combinational effects of K-ras and IGF-IR antisense oligodeoxynucleotide on proliferation and apoptosis of human pancreatic cancer Patu8988 cells].
    Shen YM; Yang XC; Zhang MH; Shen JK; Sun YH
    Ai Zheng; 2008 May; 27(5):496-504. PubMed ID: 18479599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
    Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y
    Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting for insulin-like growth factor-I receptor with short hairpin RNA for human digestive/gastrointestinal cancers.
    Wang Y; Adachi Y; Imsumran A; Yamamoto H; Piao W; Li H; Ii M; Arimura Y; Park MY; Kim D; Lee CT; Carbone DP; Imai K; Shinomura Y
    J Gastroenterol; 2010 Feb; 45(2):159-70. PubMed ID: 19902140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
    Piao W; Wang Y; Adachi Y; Yamamoto H; Li R; Imsumran A; Li H; Maehata T; Ii M; Arimura Y; Lee CT; Shinomura Y; Carbone DP; Imai K
    Mol Cancer Ther; 2008 Jun; 7(6):1483-93. PubMed ID: 18566219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
    Bauer TW; Fan F; Liu W; Camp ER; Yang A; Somcio RJ; Bucana CD; Singh R; Ellis LM
    Ann Surg Oncol; 2007 Oct; 14(10):2838-46. PubMed ID: 17653802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
    Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts.
    Min Y; Adachi Y; Yamamoto H; Imsumran A; Arimura Y; Endo T; Hinoda Y; Lee CT; Nadaf S; Carbone DP; Imai K
    Gut; 2005 May; 54(5):591-600. PubMed ID: 15831900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
    Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
    Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
    Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
    Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.
    Iwasa T; Okamoto I; Suzuki M; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
    Clin Cancer Res; 2009 Aug; 15(16):5117-25. PubMed ID: 19671857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
    Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
    Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.